Robert J. Gould - Jun 7, 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Director
Signature
/s/ Gregory Tourangeau, as attorney-in-fact for Robert J. Gould
Stock symbol
FULC
Transactions as of
Jun 7, 2022
Transactions value $
-$17,844
Form type
4
Date filed
6/8/2022, 07:33 PM
Previous filing
Jun 6, 2022
Next filing
Jun 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FULC Common Stock Options Exercise $560K +71.4K +14.1% $7.84 578K Jun 7, 2022 Direct F1
transaction FULC Common Stock Sale -$578K -71.4K -12.36% $8.09 507K Jun 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Options Exercise $0 -71.4K -45.22% $0.00 86.5K Jun 7, 2022 Common Stock 71.4K $7.84 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.35, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.